Wegovy®

Wegovy® is the brand name for high-dose semaglutide manufactured by Novo Nordisk, specifically FDA-approved for chronic weight management in adults with obesity or overweight with weight-related health conditions. Unlike Ozempic® (which is approved for diabetes), Wegovy® is formulated at higher doses specifically for weight loss.

Wegovy® works by activating GLP-1 receptors to reduce appetite, slow digestion, and help you feel fuller longer. At altRx, Wegovy® is prescribed by licensed clinicians through telehealth consultations, with ongoing support to help you achieve sustainable weight loss results.

Both Wegovy® and Ozempic® contain semaglutide and are manufactured by Novo Nordisk, but they differ in dosing and FDA approval. Ozempic® is approved for type 2 diabetes with doses up to 2mg weekly, while Wegovy® is approved specifically for weight management with doses up to 2.4mg weekly.

The higher dose in Wegovy® may provide enhanced weight loss results for some patients. Clinical trials for Wegovy® showed participants lost an average of 15-17% of their body weight versus 12-15% with Ozempic®. Your clinician will help determine which medication and dosing is right for your individual needs and health profile.

Wegovy® activates GLP-1 receptors in multiple areas of the body. In the brain, it targets appetite centers to reduce hunger signals and increase feelings of fullness. In the digestive system, it slows gastric emptying, keeping you satisfied longer after meals. It also helps regulate blood sugar by enhancing insulin secretion when needed.

The STEP clinical trial program demonstrated impressive results: participants taking Wegovy® lost an average of 15% of their body weight over 68 weeks, with many achieving clinically significant weight loss. Beyond weight reduction, studies showed improvements in blood pressure, cholesterol, blood sugar, and inflammation markers.

Most users experience a noticeable reduction in appetite and food cravings within the first week of starting Wegovy®. Meals become more satisfying with smaller portions, and constant thoughts about food or snacking tend to diminish naturally. The feeling of fullness lasts significantly longer between meals.

Initial side effects may include nausea, occasional digestive discomfort, constipation, or diarrhea—these typically improve within 2-4 weeks as your body adapts. Wegovy® dosing starts at 0.25mg weekly and increases gradually over 16-20 weeks to the full 2.4mg dose, minimizing side effects while maximizing effectiveness. Most users report steady, sustainable weight loss alongside improved energy and wellbeing.

Administration: Once-weekly subcutaneous injection using pre-filled, single-dose pen
Dosing: Escalates gradually: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg (maintenance dose), increasing every 4 weeks
Storage: Refrigerate unused pens (36-46°F); after first use, can be kept at room temperature (up to 86°F) or refrigerated for up to 28 days
Manufacturer: Novo Nordisk